Stock A000100 YUHAN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yuhan Corporation

Equities

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
71,000 KRW -0.70% Intraday chart for Yuhan Corporation +2.45% +3.20%
Apr. 24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
Mar. 07 Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,952,225 4,693,094 4,261,559 4,093,463 5,152,134 5,293,575 - -
Enterprise Value (EV) 2 2,626 4,368 3,950 3,870 5,152 5,019 4,887 4,904
P/E ratio 75.2 x 25.5 x 41.5 x 40.7 x - 34.2 x 26.9 x 23.6 x
Yield 0.85% 2.66% 0.64% 0.7% - 0.56% 0.57% 0.65%
Capitalization / Revenue 1.99 x 2.9 x 2.52 x 2.31 x 2.77 x 2.54 x 2.31 x 2.31 x
EV / Revenue 1.77 x 2.7 x 2.34 x 2.18 x 2.77 x 2.41 x 2.13 x 2.14 x
EV / EBITDA 36.9 x 30.3 x 39 x 49 x - 29.1 x 20 x 18.3 x
EV / FCF 114 x -193 x 74.7 x 93.9 x - 42.5 x 27.2 x 27.9 x
FCF Yield 0.88% -0.52% 1.34% 1.07% - 2.35% 3.67% 3.58%
Price to Book 1.67 x 2.5 x 1.96 x 1.91 x - 2.42 x 2.26 x 2.24 x
Nbr of stocks (in thousands) 75,773 72,231 75,593 75,139 74,979 74,717 - -
Reference price 3 38,914 64,874 56,327 54,476 68,800 71,000 71,000 71,000
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,480 1,620 1,688 1,776 1,859 2,083 2,293 2,296
EBITDA 1 71.19 144 101.3 79.05 - 172.4 244.2 268.5
EBIT 1 12.54 84.26 48.6 36.03 56.78 122.1 191.5 215.6
Operating Margin 0.85% 5.2% 2.88% 2.03% 3.05% 5.86% 8.35% 9.39%
Earnings before Tax (EBT) 1 54.92 239.9 126.1 94.93 142.5 207.2 261.4 297.7
Net income 1 36.61 192.8 102.6 95.14 142.5 174.1 217.8 241.1
Net margin 2.47% 11.9% 6.08% 5.36% 7.67% 8.36% 9.5% 10.5%
EPS 2 517.1 2,542 1,357 1,339 - 2,078 2,644 3,014
Free Cash Flow 3 23,000 -22,623 52,849 41,234 - 118,027 179,409 175,625
FCF margin 1,553.71% -1,396.58% 3,131.24% 2,321.92% - 5,665.51% 7,825.08% 7,650.01%
FCF Conversion (EBITDA) 32,307.01% - 52,188.42% 52,163.18% - 68,450.29% 73,460.74% 65,418.5%
FCF Conversion (Net income) 62,821.54% - 51,518.9% 43,338.05% - 67,802.45% 82,391.31% 72,843.22%
Dividend per Share 2 329.1 1,728 362.8 381.0 - 396.3 403.5 461.9
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 451.5 424 410.9 483 431.5 450.5 443 495.7 483.1 471.8 533.7 536.4 542.8
EBITDA 1 - - - 27.65 6.006 28.34 - 38.25 11.93 21 53 37 52
EBIT 1 6.516 4.752 6.102 16.94 -4.538 17.53 22.63 27.08 0.8833 17.02 28.59 28.27 43.27
Operating Margin 1.44% 1.12% 1.49% 3.51% -1.05% 3.89% 5.11% 5.46% 0.18% 3.61% 5.36% 5.27% 7.97%
Earnings before Tax (EBT) 1 36.4 19.57 28.32 43.43 21.78 1.398 35.81 13.74 19.31 29.35 39.5 49.8 49.2
Net income 1 30.69 17.13 15.93 34.08 7.526 37.6 22.24 8.678 19.59 27.64 32.73 36.07 41.43
Net margin 6.8% 4.04% 3.88% 7.06% 1.74% 8.35% 5.02% 1.75% 4.06% 5.86% 6.13% 6.72% 7.63%
EPS - - - - - - 296.2 - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 10/29/21 2/16/22 4/29/22 7/28/22 11/14/22 2/23/23 5/15/23 7/28/23 11/14/23 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 326 326 312 223 - 274 407 390
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 2 23,000 -22,623 52,849 41,234 - 118,027 179,409 175,625
ROE (net income / shareholders' equity) 2.22% 10.9% 5.24% 4.59% 6.92% 8.04% 9.55% 9.47%
ROA (Net income/ Total Assets) 1.71% 8.44% 4.22% 3.85% - 5.89% 6.99% 6.73%
Assets 1 2,146 2,283 2,429 2,468 - 2,954 3,114 3,585
Book Value Per Share 3 23,241 25,984 28,703 28,542 - 29,380 31,412 31,687
Cash Flow per Share 3 928.0 2,137 1,468 1,401 - 2,379 2,958 3,774
Capex 1 42.8 51.5 46.2 58.3 - 51.8 51.7 69.9
Capex / Sales 2.89% 3.18% 2.73% 3.28% - 2.49% 2.26% 3.04%
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Yuhan Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
71,000 KRW
Average target price
85,674 KRW
Spread / Average Target
+20.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A000100 Stock
  4. Financials Yuhan Corporation